Dr. Francois Nader, MD, MBA
Dr. Francois Nader is a life sciences value builder, entrepreneur and philanthropist.
Dr. Nader serves as chairman of BenevolentAI (BAI), Talaris Therapeutics (TALS) and Neurvati Neurosciences, as board director of Moderna (MRNA) and RING Therapeutics and as senior advisor of Blackstone Life Sciences. He also serves on the executive committee of the Lebanese American University (LAU) board of trustees, on the board of the American Task Force on Lebanon (ATFL) and as an advisor to LIFE.
Dr. Nader is the recipient of the Lebanese National Order of Merit, the Ernst and Young National Life Science Entrepreneur of the Year® award and the Ellis Island Medal of Honor.
Previously, Dr. Nader was Chief Executive Officer of NPS Pharma. During his tenure, he transformed NPS Pharma into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases. Before NPS, Dr. Nader was a venture partner at Care Capital. Prior, he served on the North America Leadership Team of Aventis and its predecessor companies holding several executive positions including senior vice-president, integrated healthcare markets and North America medical and regulatory affairs. Previously, he led the global commercial operations at the Pasteur Vaccins’ division of Rhone-Poulenc.
Dr. Nader is past chairman of BioNJ, Acceleron Pharma (XLRN) acquired by Merck, Prevail Therapeutics (PRVL) acquired by Lilly and served as board director of Alexion (ALXN) acquired by Astra Zeneca, Clementia Pharmaceuticals (CMTA) acquired by IPSEN, Advanced Accelerator Applications (AAAP) acquired by Novartis, Baxalta (BXLT) acquired by Shire, and Noven (NOVN) acquired by Hisamitsu.
Dr. Nader earned his French Doctorate in Medicine from St. Joseph University (Lebanon) and his Physician Executive MBA from the University of Tennessee.